Compare Medpace Holdings Inc (MEDP) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs DENTSPLY SIRONA Inc — how do they compare? Medpace Holdings Inc trades at $617.27 (market cap $16.82B), while DENTSPLY SIRONA Inc trades at $8.81 (market cap $1.73B). The key difference: Medpace Holdings Inc is far larger — about 9.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| MEDP | XRAY | |
|---|---|---|
Market Cap | $16.82B | $1.73B |
Volume | 223,093 | 6,198,582 |
Sector | Health | Health |
52-Week High | $630.19 | $14.68 |
52-Week Low | $393.42 | $8.52 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | $16.44B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
